Article

Nidek MC-300 photocoagulator, YC-1800 YAG laser systems available

Washington, DC &#8212 Nidek Inc. has received FDA marketing clearance for commercial release of its new MC-300 multicolor laser photocoagulator system. The company also announced that its new state-of-the-art YC-1800 ophthalmic YAG laser system is available for sale to the U.S. market.

April 18 - Washington, DC - Nidek Inc. has received FDA marketing clearance for commercial release of its new MC-300 multicolor laser photocoagulator system. The company also announced that its new state-of-the-art YC-1800 ophthalmic YAG laser system is available for sale to the U.S. market.

The MC-300 laser system has been commercially available in international markets and has received outstanding reviews and clinical results from retinal specialists in Asia and Europe.

The Nidek MC-300 is an advanced multi-color (red, yellow, and green) diode-pumped solid-state laser system. The new laser delivers three unique laser wavelengths (659, 561, and 532 nm) that are ideal for retinal applications, disease treatments, and management. The new retinal photocoagulator features advanced software technologies for accurate and precise energy delivery to the retina. The MC-300 laser can be mounted for slit-lamp delivery and requires a standard electric outlet, offering retinal surgeons with advanced delivery capabilities and versatility in either an operating room or in-office use.

The Nidek YC-1800 YAG laser system is an advanced ophthalmic laser platform that combines innovative laser delivery and output technologies, improved operability, fast operation, super adjustable Nd:YAG offset, and compact design with versatility for combination laser systems.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.